The UCLA Alzheimer's Disease Research Center (ADRC) supports cutting edge research in an environment that mentors junior investigators;attracts numerous researchers;hosts a pilot project program that allows investigators to gamer preliminary data for more advanced studies;collaborates with the National Alzheimer's Coordination Center (NACC) as well as other Alzheimer disease (AD) related investigators locally, nationally and internationally;extends AD research to women and minorities;and works closely with community and advocacy groups including the Alzheimer's Association. The UCLA ADRC is comprised of 6 cores and proposes 3 projects in this renewal application. Cores include: Administrative, Clinical, Data Management and Statistics, Neuropathology, Recruitment and Education, and Neuroimaging and Biomarkers. The three projects include an investigation of MRI techniques applicable to clinical trials and population studies (Project 1;Liana Apostolova;Junior Investigator), a study of the comparative information to be gained from FDDNP and Pittsburg Compound B molecular imaging and their relationship to CSF and plasma biomarkers (Project 2;Gary Small);and a study of antibodies that inhibit amyloid 6 and tau aggregation and may represent novel interventions in AD (Project 3;David Eisenberg). The Theme of the UCLA ADRC is The Therapeutic Imperative, emphasizing the urgency of developing new treatments for AD. Resource use, core organization, project selection, collaboration, and educational activities are prioritized according to their integration with the Center theme. Clinical Core is following 120 patients;Recruitment and Education Core sponsored lectures reaching 20,000 participants;Neuropathology Core performed autopsies on Center patients who died, and non-Center patients to augment tissue distribution. This application has a major emphasis on biomarkers as a key aspect of advancing new therapies for AD. A familial AD cohort is included in this renewal application and a new minority site (Harbor View Medical Center) has been added. Innovations in advancing research are proposed in each Core of this proposal. Each core has responded to criticisms and recommendations from the 2008 review in this renewal application.

Public Health Relevance

The UCLA ADRC theme of the Therapeutic Imperative reflects the commitment of UCLA investigators to shortening the time horizon to finding effective treatments for AD. Biomarkers are a key element in the search for effective therapies and will be advanced by investigators collaborating with the UCLA ADRC. Attracting minorities to research is critically important, and UCLA has been successful in this difficult task.

National Institute of Health (NIH)
National Institute on Aging (NIA)
Specialized Center (P50)
Project #
Application #
Study Section
Special Emphasis Panel (ZAG1-ZIJ-4 (J2))
Program Officer
Phelps, Creighton H
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
University of California Los Angeles
Schools of Medicine
Los Angeles
United States
Zip Code
Jutkowitz, Eric; MacLehose, Richard F; Gaugler, Joseph E et al. (2017) Risk Factors Associated With Cognitive, Functional, and Behavioral Trajectories of Newly Diagnosed Dementia Patients. J Gerontol A Biol Sci Med Sci 72:251-258
Sokolow, Sophie; Li, Xiaohui; Chen, Lucia et al. (2017) Deleterious Effect of Butyrylcholinesterase K-Variant in Donepezil Treatment of Mild Cognitive Impairment. J Alzheimers Dis 56:229-237
Ringman, John M; Casado, Maria; Van Berlo, Victoria et al. (2017) A novel PSEN1 (S230N) mutation causing early-onset Alzheimer's Disease associated with prosopagnosia, hoarding, and Parkinsonism. Neurosci Lett 657:11-15
Jefferson-George, Kyra S; Wolk, David A; Lee, Edward B et al. (2017) Cognitive decline associated with pathological burden in primary age-related tauopathy. Alzheimers Dement 13:1048-1053
Katsumata, Yuriko; Nelson, Peter T; Ellingson, Sally R et al. (2017) Gene-based association study of genes linked to hippocampal sclerosis of aging neuropathology: GRN, TMEM106B, ABCC9, and KCNMB2. Neurobiol Aging 53:193.e17-193.e25
Ringman, John M (2017) Update on Alzheimer's and the Dementias: Introduction. Neurol Clin 35:171-174
Qian, Jing; Hyman, Bradley T; Betensky, Rebecca A (2017) Neurofibrillary Tangle Stage and the Rate of Progression of Alzheimer Symptoms: Modeling Using an Autopsy Cohort and Application to Clinical Trial Design. JAMA Neurol 74:540-548
Chang, Timothy S; Teng, Edmond; Elashoff, David et al. (2017) Optimizing Effect Sizes With Imaging Enrichment and Outcome Choices for Mild Alzheimer Disease Clinical Trials. Alzheimer Dis Assoc Disord 31:19-26
Blanken, Anna E; Hurtz, Sona; Zarow, Chris et al. (2017) Associations between hippocampal morphometry and neuropathologic markers of Alzheimer's disease using 7 T MRI. Neuroimage Clin 15:56-61
Kim, Julia; Schweizer, Tom A; Fischer, Corinne E et al. (2017) The Role of Cerebrovascular Disease on Cognitive and Functional Status and Psychosis in Severe Alzheimer's Disease. J Alzheimers Dis 55:381-389

Showing the most recent 10 out of 704 publications